Literature DB >> 9618440

Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11.

P K Powell1, I Wolf, R Jin, J M Lasker.   

Abstract

20-Hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) is a principal arachidonic acid (AA) metabolite formed via P450-dependent oxidation in hepatic and renal microsomes. Although 20-HETE plays an important role in the regulation of cell and/or organ physiology, the P450 enzyme(s) catalyzing its formation in humans remain undefined. In this study, we have characterized AA omega-hydroxylation to 20-HETE by human hepatic microsomes and identified the underlying P450s. Analysis of microsomal AA omega-hydroxylation revealed biphasic kinetics (KM1 and VMAX1 = 23 microM and 5.5 min-1; KM2 and VMAX2 = 144 microM and 18.8 min-1) consistent with catalysis by at least two enzymes. Of the human P450s examined, CYP4A11 and CYP4F2 were both potent AA omega-hydroxylases, exhibiting rates of 15.6 and 6.8 nmol 20-HETE formed/min/nmol P450, respectively. Kinetic parameters of 20-HETE formation by CYP4F2 (KM = 24 microM; VMAX = 7.4 min-1) and CYP4A11 (KM = 228 microM; VMAX = 49.1 min-1) resembled the low and high KM components, respectively, found in liver microsomes. Antibodies to CYP4F2 markedly inhibited (93.4 +/- 6%; n = 5) formation of 20-HETE by hepatic microsomes, whereas antibodies to CYP4A11 were much less inhibitory (13.0 +/- 9%; n = 5). Moreover, a strong correlation (r = 0.78; P < .02) was found between microsomal CYP4F2 content and AA omega-hydroxylation among nine subjects. The correlation (r = 0.76; P < .02) also noted between CYP4A11 content and 20-HETE formation stemmed from the relationship (r = 0.83; P < . 02) between hepatic CYP4A11 and CYP4F2 levels in the subjects. Finally, immunoblot analysis revealed that in addition to liver, both P450s also were expressed in human kidney. Our results indicate that AA omega-hydroxylation in human liver is catalyzed by two enzymes of the CYP4 gene family, namely CYP4F2 and CYP4A11, and that CYP4F2 underlies most 20-HETE formation occurring at relevant AA concentrations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618440

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  60 in total

1.  CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Authors:  Han-Jing Cen; Wu-Tao Zeng; Xiu-Yu Leng; Min Huang; Xiao Chen; Jia-Li Li; Zhi-Ying Huang; Hui-Chang Bi; Xue-Ding Wang; Yan-Ling He; Fan He; Rui-Na Zhou; Qi-Shan Zheng; Li-Zi Zhao
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 2.  Structural control of cytochrome P450-catalyzed ω-hydroxylation.

Authors:  Jonathan B Johnston; Hugues Ouellet; Larissa M Podust; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2010-08-19       Impact factor: 4.013

3.  CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant.

Authors:  Mariko Nakano; Edward J Kelly; Constanze Wiek; Helmut Hanenberg; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2012-07-06       Impact factor: 4.436

4.  GPR75 receptor mediates 20-HETE-signaling and metastatic features of androgen-insensitive prostate cancer cells.

Authors:  Sofia Cárdenas; Cecilia Colombero; Laura Panelo; Rambabu Dakarapu; John R Falck; Monica A Costas; Susana Nowicki
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-11-21       Impact factor: 4.698

Review 5.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

6.  Role of 20-Hydroxyeicosatetraenoic Acid (20-HETE) in Androgen-Mediated Cell Viability in Prostate Cancer Cells.

Authors:  Cecilia Colombero; Daniela Papademetrio; Paula Sacca; Eduardo Mormandi; Elida Alvarez; Susana Nowicki
Journal:  Horm Cancer       Date:  2017-06-21       Impact factor: 3.869

Review 7.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

8.  The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics.

Authors:  Scott Michaels; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2014-05-09       Impact factor: 3.922

9.  Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors.

Authors:  N Rimmerman; H B Bradshaw; A Basnet; B Tan; Theodore S Widlanski; J M Walker
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-09-02       Impact factor: 3.072

10.  Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies.

Authors:  Vandana Hirani; Anton Yarovoy; Anita Kozeska; Ronald P Magnusson; Jerome M Lasker
Journal:  Arch Biochem Biophys       Date:  2008-07-16       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.